Alkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Alkermes (ALKS) PT Lowered to $45 at BofA/Merrill Lynch; Sees Loss in 2015February 25, 2015 7:32 AM